Title | Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. |
Publication Type | Journal Article |
Year of Publication | 2013 |
Authors | Hess, Connie N., Phillip J. Schulte, Kristin L Newby, Philippe Gabriel Steg, Anthony J. Dalby, Marc J. Schweiger, Basil S. Lewis, Paul W. Armstrong, Robert M. Califf, Frans van de Werf, and Robert A. Harrington |
Journal | Eur Heart J Acute Cardiovasc Care |
Volume | 2 |
Issue | 3 |
Pagination | 246-55 |
Date Published | 2013 Sep |
ISSN | 2048-8734 |
Keywords | Acute Coronary Syndrome, Eptifibatide, Female, Hemorrhage, Humans, Infusions, Intravenous, Male, Middle Aged, Myocardial Infarction, Myocardial Ischemia, Peptides, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Recurrence, Risk Factors, Treatment Outcome |
Abstract | BACKGROUND AND OBJECTIVES: Eptifibatide is indicated during percutaneous coronary intervention (PCI) with continuation for 18-24 hours post procedure but is associated with bleeding. We examined the efficacy and safety of shorter post-PCI eptifibatide infusions in high-risk non-ST-segment elevation acute coronary syndrome (NSTE ACS) patients.METHODS: EARLY ACS patients treated with PCI and eptifibatide were grouped by post-procedure infusion duration: <10, 10-13, 13-17, and 17-25 (per protocol) hours. Adjusted estimated event rates for 96-hour death/myocardial infarction (MI)/recurrent ischaemia requiring urgent revascularization (RIUR), 30-day death/MI, post-PCI packed red blood cell (PRBC) transfusion, and GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) moderate/severe bleeding were obtained using inverse-propensity weighting to account for informative censoring of infusions.RESULTS: Among 3271 eptifibatide-treated PCI patients, there were 66 96-hour death/MI/RIUR events, 94 30-day death/MI events, 127 PRBC transfusions, and 115 GUSTO moderate/severe bleeds. Compared with per protocol, patients receiving post-PCI infusions <10 hours had similar adjusted estimated rates of 96-hour death/MI/RIUR (absolute difference 0.021 higher; 0.040 vs. 0.019, 95% CI -0.023 to 0.064; p=0.35) and 30-day death/MI (0.020 higher; 0.046 vs. 0.026, 95% CI -0.021 to 0.062; p=0.34). There were also no differences in ischaemic outcomes between infusions of 10-17 hours and per-protocol infusions. Adjusted estimated rates of PRBC transfusion were higher for the <10-hour infusion group compared with per protocol (0.048 higher; 0.079 vs. 0.031, 95% CI 0.005 to 0.091, p=0.03) but were similar for other groups. Adjusted GUSTO moderate/severe bleeding rates were similar to per-protocol rates for all groups.CONCLUSIONS: In high-risk NSTE ACS patients, post-PCI eptifibatide infusions <18 hours were not associated with worse ischaemic outcomes. Shorter eptifibatide infusions in this population may be feasible. |
DOI | 10.1177/2048872612474922 |
Alternate Journal | Eur Heart J Acute Cardiovasc Care |
Original Publication | Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. |
PubMed ID | 24222836 |
PubMed Central ID | PMC3821813 |
Grant List | T32 HL079896 / HL / NHLBI NIH HHS / United States T32 HL069749 / HL / NHLBI NIH HHS / United States P01CA142538 / CA / NCI NIH HHS / United States P01 CA142538 / CA / NCI NIH HHS / United States 5T32HL069749-09 / HL / NHLBI NIH HHS / United States |
Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
Project: